I was confusing two different stocks with similar names when I asked about the Rett syndrome study. I admitted that and apologized to the board. The brain drain does that sometimes.
I also deleted several OT pump pieces for Neurotrope from the Anavex board.
I don't own NTRP because I don't like the recent dilution and because of my disabilities I rely highly on the imagery of charting. I don't like the NTRP chart so no matter what the fundamentals are I would not buy in at this time.
In a nutshell - Anavex drugs seem to be restoring cellular homeostasis and may work on a much larger variety of CNS indications. They may also work in other areas of the body (example - visceral issues related to autonomic dysfunction, which is why I got up so damn early this morning, restored to homeostasis ).
Since some of the super responders to 2-73 regained skills they thought they had lost (reading of sheet music is the best example because it uses both long term and short term memory). I don't think the growth of new synapses is necessary - it seems to be more of a housekeeping task.
Now - in things like genetic early onset Alzheimer's and Rett Syndrome it is quite possible that correction of a biological process, development of new synapses, will help.
As I just posted on the board - no one can say yet if the two compounds will be competitive, have different applications, or be synergistic.
News 
Market Data 
Discover 
